

SCIENTIFIC PROGRAMME

All scientific sessions take place in the Clyde Auditorium unless otherwise noted.

SUNDAY 9 NOVEMBER

SS1	11.00–12.30	Satellite Symposium: Pfizer HAART: Escaping the ‘Red-Queen Effect’. Will new treatments enable us to win the evolution challenge?
SS1CH		<i>Chairs: Santiago Moreno (Spain) Mark Nelson (UK)</i>
SS1.1		“Begin at the beginning and go on until you come to the end. Read the directions and directly you will be directed in the right direction” The role of CCR5 antagonists in ART-strategy; when and how to use them <i>Jürgen Rockstroh (Germany)</i>
SS1.2		“Curioser and curioser” Nucleoside sparing regimens: why do we need them? <i>Graeme Moyle (UK)</i>
SS1.3		“I think I should understand that better . . .” How important is CD4 count and how to increase it? <i>Yves Levy (France)</i>
		Panel discussion
	12.30–13.30	LUNCH
SS2	13.30–15.00	Satellite Symposium: Merck Sharp & Dohme Reaching new heights in HIV management
SS2CH		<i>Chair: Brian Gazzard (UK)</i>
SS2CH	13.30–13.35	Opening remarks <i>Brian Gazzard (UK)</i>
SS2.1	13.35–13.55	HIV Treatment Goals: updated guidelines and new therapeutic opportunities <i>Brian Gazzard (UK)</i>
SS2.2	13.55–14.20	The evolving role of raltegravir in HIV management <i>Calvin Cohen (USA)</i>
SS2.3	14.20–14.45	New possibilities in HIV management: real-world experience <i>Christine Katlama (France)</i>
	14.45–14.55	Panel discussion
SS2CH	14.55–15.00	Closing remarks <i>Brian Gazzard (UK)</i>
	15.00–15.30	COFFEE
SS3	15.30–17.00	Satellite Symposium: GlaxoSmithKline PLC Pieces of the puzzle – unlocking the potential of personalised medicine
SS3CH		<i>Chair: Peter Reiss (The Netherlands)</i>
SS3CH	15.30–15.40	Introduction <i>Peter Reiss (The Netherlands)</i>
SS3.1	15.40–16.00	Translating evidence into practice – efficacy of NRTIs <i>Carlo-Federico Perno (Italy)</i>



SCIENTIFIC PROGRAMME (continued)

SS3.2	16.00–16.20	Personalisation – patients and choices – understanding safety and long-term treatments <i>Esteban Martínez (Spain)</i>
	16.20–16.30	Questions and answers for Professor Perno and Professor Martínez
SS3.3	16.30–16.50	A new way of thinking – sharing experiences from cardiovascular risk in rheumatoid arthritis <i>George Kitas (UK)</i>
	16.50–16.55	Questions and answers for Professor Kitas
SS3CH	16.55–17.00	Closing remarks <i>Peter Reiss (The Netherlands)</i>
	17.00–17.30	COFFEE
	17.30–18.00	Official Opening <i>Ed Byrne, Executive Dean of Biomedicine, Head of University College London Medical School (UCLMS) and Vice Provost (Health) (UK)</i> <i>Brian Williams, President, Royal College of Physicians and Surgeons of Glasgow (UK)</i>
KL	18.00–19.30	Keynote Lectures
KL1	18.00–18.30	Pathogenesis of HIV infection: implications for treatment and prevention <i>Clifford Lane (USA)</i>
KL2	18.30–19.00	How will we use the new ART drugs? <i>Christine Katlama (France)</i>
KL3	19.00–19.30	The implications beyond public health if we don't manage the HIV epidemic <i>Alan Whiteside (South Africa)</i>

19.30–20.30 WELCOME RECEPTION

MONDAY 10 NOVEMBER

O11	08.30–10.25	Antiretroviral Resistance: What You Want to Know
O11CH		<i>Chairs: Jonathan Schapiro (Israel)</i> <i>Anders Sönnnerborg (Sweden)</i>
O111	08.30–08.50	Global impact of HIV drug resistance <i>Deenan Pillay (UK)</i>
O112	08.50–09.05	Trends in transmitted HIV drug resistance among non-B subtypes in the UK <i>Daniella Chilton (UK)</i>
O113	09.05–09.20	HIV-1 clade C resistance genotypes after first virological failure in a large community ART programme <i>Catherine Orrell (South Africa)</i>
O114	09.20–09.35	NNRTI mutations are efficiently transmitted within clusters of new HIV infections <i>Mark Wainberg (Canada)</i>

SCIENTIFIC PROGRAMME (continued)

O115	09.35–09.55	Importance of detecting minority variants in the clinical management of HIV <i>Dan Kuritzkes (USA)</i>
	09.55–10.25	Panel discussion and questions
	10.25–10.55	COFFEE
O12	10.55–12.40	Essential Pharmacology
O12CH		<i>Chairs: David Back (UK)</i> <i>Janet Darbyshire (UK)</i>
O121	10.55–11.10	Prevalence of drug interactions between antiretroviral and co-administered drugs at the MOI teaching and referral hospital (Ampath), Eldoret, Kenya <i>Saye Khoo (UK)</i>
O122	11.10–11.25	To overdose or underdose? The question of Kaletra in children in the UK/Irish Collaborative HIV Paediatric Study (CHIPS) <i>Sarah Walker (UK)</i>
O123	11.25–11.45	Drug interactions that really matter <i>Saye Khoo (UK)</i>
O124	11.45–12.00	Efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy? <i>Catherine Orrell (South Africa)</i>
O125	12.00–12.15	Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients <i>Cissy Kityo (Uganda)</i>
	12.15–12.40	Panel discussion
	12.40–14.10	LUNCH AND POSTERS (including Poster Discussion Sessions)
Hall 4, Room 1	13.00–14.00	Treatment Strategies: Naïve Patients
PCH		<i>Chairs: Brian Gazzard (UK)</i> <i>Alain Volny-Anne (France)</i>
P1		Clinical effect of interleukin-2 (IL-2) immuno-adjuvant treatment in HIV+ advanced naïve patients <i>Camilla Tincati (Italy)</i>
P2		Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204 <i>Katia Boven (USA)</i>
P3		Impact of antiretroviral dosing and daily pill burden on viral rebound rates in naïve patients receiving a tenofovir-based regimen <i>Andrea Antinori (Italy)</i>
P53		Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results <i>José Gatell (Spain)</i>



SCIENTIFIC PROGRAMME (continued)

P54		48-week outcomes following switch from AZT/3TC to FTC/TDF (TVD) vs. continuing on AZT/3TC: 48-week interim analysis of the RECOMB trial <i>Esteban Ribera (Spain)</i>
P306		NRTI backbone pairs for treatment-naïve adults with HIV infection: a UK economic evaluation <i>Edward Hutt (USA)</i>
Hall 4, Room 2	13.00–14.00	Strategies for the Experienced: Immunology and Inflammation, the Lung, and Sex
PCH		<i>Chairs: Judith Currier (USA)</i> <i>Simone Marcotullio (Italy)</i>
P61		Simplification of therapy (ART) with efavirenz/emtricitabine/tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients <i>Ben Young (USA)</i>
P167		Effect of a fixed-dose combination of emtricitabine, tenofovir and efavirenz on adherence and treatment acceptability (ADONE study) <i>Franco Maggiolo (Italy)</i>
P70		Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression <i>Helen Byakwaga (Australia)</i>
P297		Changes in CCR5+ cells and antigen-specific CD4+ T-cells during monotherapy with a CCR5 antagonist SCH532706 compared with combination therapy <i>Sarah Pett (Australia)</i>
P213		D-dimer and anti-coagulation activity markers in children and adolescents with HIV infection <i>Giuseppe Pontrelli (Italy)</i>
P299		What about primary pulmonary hypertension in HIV infection in the era of combination antiretroviral therapy? <i>Murielle Mary-Krause (France)</i>
P71		Virological treatment outcome under HAART: does sex matter? <i>Annette Haberl (Denmark)</i>
	14.10–14.20	The HIV Research Trust: Report on Progress <i>Robert Souhami, Chairperson of the HIV Research Trust (UK)</i>
O13	14.20–16.30	Headlines from Resource-poor Settings IAS Session
O13CH		<i>Chairs: Pedro Cahn (Argentina)</i> <i>Ade Fakoya (International AIDS Alliance, and UK)</i>
O131	14.20–14.40	Where are we with National and International guidelines? <i>Elly Katabira (Uganda)</i>
O132	14.40–15.00	Second-line in ART in the Developing World <i>James Hakim (Zimbabwe)</i>

SCIENTIFIC PROGRAMME (continued)

O133	15.00–15.20	HIV/TB: when is it safe to start HAART? <i>Robin Wood (South Africa)</i>
O134	15.20–15.40	HIV disease management and challenges in Eastern Europe and Central Asia <i>Alexey Bobrik (Russian Federation)</i>
O135	15.40–16.00	Seek and treat for optimal prevention of HIV/AIDS (STOP HIV/AIDS) <i>Julio Montaner (Canada)</i>
	16.00–16.30	Panel discussion
	16.30–17.00	COFFEE
SS4	17.00–18.30	Satellite Symposium: Boehringer Ingelheim GmbH Aiming for the long-term: focus on the individual
SS4CH		<i>Chair: José Gatell (Spain)</i>
SS4CH	17.00–17.05	Welcome and introduction <i>José Gatell (Spain)</i>
SS4.1	17.05–17.25	Considering the individual – principles of treatment choice <i>Laura Waters (UK)</i>
SS4.2	17.25–17.50	Initiating and maintaining HAART – aiming for the long term in treatment-naïve patients <i>Georg Behrens (Germany)</i>
SS4.3	17.50–18.20	Understanding PI resistance – aiming for the long term in treatment-experienced patients <i>Anna Maria Geretti (UK)</i>
	18.20–18.30	Panel discussion

TUESDAY 11 NOVEMBER

O21	08.30–09.50	The CNS, Immune Response and Treatment Interruption Revisited
O21CH		<i>Chairs: Margaret Johnson (UK) Stefano Vella (Italy)</i>
O211	08.30–08.50	HIV and the brain: neuro-inflammation long-term, CNS control of HIV replication, brain disease in suppressed patients and differential penetration of drugs <i>David Clifford (USA)</i>
O212	08.50–09.05	Rate of change in CD4 counts in patients with stable HIV viraemia <i>Amanda Mocroft (UK)</i>
O213	09.05–09.20	CD4-guided STI in patients responding to HAART <i>Franco Maggiolo (Italy)</i>
O214	09.20–09.35	The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy <i>Calvin Cohen (USA)</i>
	09.35–09.50	Panel discussion
	09.50–10.20	COFFEE



SCIENTIFIC PROGRAMME (continued)

O22	10.20–12.15	Children: From Birth to Longevity
O22CH		<i>Chairs: Hermione Lyall (UK) Ian Weller (UK)</i>
O221	10.20–10.35	Antiretroviral Pregnancy Registry (APR) at 10,000 prospective reports <i>Karen Beckerman (USA)</i>
O222	10.35–10.50	Treatment interruption in children with chronic HIV-infection: the results of the paediatric European network for treatment of AIDS (PENTA) 11 trial <i>Di Gibb (UK)</i>
O223	10.50–11.10	Optimising paediatric treatment for long-term survival. Adult survivors of congenital HIV infection: what problems will they have? <i>Hermione Lyall (UK)</i>
	11.10–11.25	Panel discussion
O224	11.25 –12.15	Special Guest Lecture The early AIDS Epidemic in the US: views from Atlanta and Hollywood <i>Harold Jaffe (UK)</i>
	12.15–13.45	LUNCH AND POSTERS (including Poster Discussion Sessions)
CoS Lomond Auditorium	12.25–13.45	Community Session Can HAART Prevent HIV Transmission?
CoSCH		<i>Chairs: Sean Hosein (Canada) Alain Volny-Anne (France)</i> Earlier this year the Swiss Federal AIDS Commission published a paper stating that having an undetectable viral load made HIV positive people non-infectious. This position paper has incited intense controversy, being published against a background of increasing criminalisation of HIV transmission, difficulty of disclosure, and the psychological burden of living with a stigmatised and chronic illness. The internationally renowned panel members will each make a 10-minute presentation on their perspective that will serve as a foundation for the insightful and spirited discussion that will follow.
CoS.1		<i>Bernard Hirschel (Switzerland)</i>
CoS.2		<i>Cate Hankins (Switzerland)</i>
CoS.3		<i>Paul MacPherson (Canada)</i>
CoS.4		<i>Bruno Spire (France)</i>

SCIENTIFIC PROGRAMME (continued)

Hall 4, Room 1		12.30–13.30	Adverse Events
PCH			<i>Chairs: Simon Mallal (Australia) Fiona Mulcahy (Ireland)</i>
P128			Kidney tubular abnormalities in HIV patients treated with tenofovir with normal glomerular function: results of a prospective study on 284 patients <i>Pablo Labarga (Spain)</i>
P150			Frequency of bone abnormalities and associated factors in a Spanish cohort of HIV-infected patients <i>Anna Bonjoch (Spain)</i>
P234			Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction <i>Massimo Giola (Italy)</i>
P288			Predictors of immune reconstitution inflammatory syndrome associated with Kaposi sarcoma (IRIS-KS) in a rural area of Mozambique <i>Emilio Letang (Spain)</i>
P289			Impact of HIV treatment on clearance of human papillomavirus (HPV) infection in HIV-infected women <i>Deborah Konopnicki (Belgium)</i>
Hall 4, Room 2		12.30–13.30	Treatment Strategies: Experienced Patients
PCH			<i>Chairs: Andrzej Horban (Poland) Andrew Phillips (UK)</i>
P20			Raltegravir: a potent and safe integrase inhibitor with a favourable impact on cardiovascular and liver profile <i>Francisco Blanco (Spain)</i>
P21			POWER 1 and 2: combined final 144-week efficacy and safety results for darunavir/ritonavir (DRV/r) 600/100 mg BID in treatment-experienced HIV patients <i>Christine Katlama (France)</i>
P22			Phase III TITAN week 96 final analysis: efficacy/safety of darunavir/r (DRV/r) vs. lopinavir/r (LPV/r) in LPV-naïve, treatment-experienced patients <i>Christine Katlama (France)</i>
P23			Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials <i>Nathan Clumeck (Belgium)</i>
O23		13.45–15.00	Hepatic Headlines
O23CH			<i>Chairs: Antonella d'Arminio Monforte (Italy) Stephen Storer (USA)</i>
O231		13.45–14.00	Cryptogenic liver disease, steatosis, portal hypertension, transaminitis and antiretrovirals <i>Stanislas Pol (France)</i>



SCIENTIFIC PROGRAMME (continued)

O232	14.00–14.15	What's new in hepatitis C? <i>Vincent Soriano (Spain)</i>
O233	14.15–14.30	Surrogate markers for liver damage: how can we measure the extent of fibrosis and disease without biopsy? <i>Massimo Puoti (Italy)</i>
	14.30–15.00	Panel discussion
CS1	15.00–16.30	Assessment of the Sick HIV-positive Returning Traveller: Case Studies Session held in collaboration with European AIDS Clinical Society
CS1CH		<i>Chairs: Manuel Battegay (Switzerland)</i> <i>Peter Reiss (The Netherlands)</i> <i>Panel: Nathan Clumeck (Belgium)</i> <i>Bob Colebunders (Belgium)</i> <i>John Gill (Canada)</i> <i>Alison Grant (UK)</i> <i>Roy Gulick (USA)</i> <i>Christoph Hatz (Switzerland)</i>
	15.20–16.10	Cases
CS1.1		• Traveller going to tropical region <i>Aisling Loy (Ireland)</i>
CS1.2		• Immigrant arriving from sub-Saharan Africa <i>Michele van Vugt (The Netherlands)</i>
CS1.3		• Traveller returning with diarrhoea <i>Emilio Letang (Spain)</i>
CS1.4		• Traveller returning with fever <i>Yves van Laethem (Belgium)</i>
CS1.5	16.10–16.30	Mini-review: Important issues considering sick HIV-positive returning traveller or immigrant from a tropical region <i>Christoph Hatz (Switzerland)</i>
	16.30–17.00	COFFEE
SS5	17.00–18.30	Satellite Symposium: Bristol-Myers Squibb The burden of choice
SS5CH		<i>Chair: Jürgen Rockstroh (Germany)</i>
SS5CH	17.00–17.10	Introduction <i>Jürgen Rockstroh (Germany)</i>
SS5.1	17.10–17.35	Why NNRTIs should be the standard in treatment initiation <i>Mark Nelson (UK)</i>
SS5.2	17.35–18.00	Why PIs should be the standard in treatment initiation <i>Calvin Cohen (USA)</i>
	18.00–18.20	Interactive discussion session <i>Calvin Cohen, Mark Nelson and Jürgen Rockstroh</i>
SS5.3	18.20–18.30	Is choice still a burden? Keep it simple! <i>Jürgen Rockstroh (Germany)</i>
	18.30	Close

SCIENTIFIC PROGRAMME (continued)

ES1 Lomond Auditorium	18.30–20.00	Evening Symposium: Abbott Clinical dialogues: Face-to-face with today's practice challenges
ES1CH		<i>Chair: Ed Wilkins (UK)</i>
ES1CH	18.30–18.35	Welcome <i>Ed Wilkins (UK)</i>
ES1.1	18.35–18.55	Flexible treatment regimens: A prelude to improved outcomes? <i>François Raffi (France)</i>
ES1.2	18.55–19.15	Case study dialogue: Addressing the complexities of long-term ARV treatment <i>François Raffi (France)</i>
		Panel discussion <i>Moderated by Ed Wilkins (UK), joined by Bruno Spire (France), François Raffi (France) and Pere Domingo (Spain)</i>
ES1.3	19.15–19.35	Lipoatrophy: Untangling the differences among ARVs <i>Pere Domingo (Spain)</i>
ES1.4	19.35–19.55	Case study dialogue: Reflecting on lipoatrophy and body fat changes <i>Ed Wilkins (UK)</i>
		Panel discussion <i>Moderated by Ed Wilkins (UK), joined by Bruno Spire (France), François Raffi (France) and Pere Domingo (Spain)</i>
ES1CH	19.55–20.00	Summary and close <i>Ed Wilkins (UK)</i>
ES2 Hall 2	18.30–20.00	Evening Symposium: Tibotec, a division of Janssen-Cilag Ltd Spanning the treatment spectrum for HIV-1-infected patients: A new era?
ES2CH		<i>Chair: Anton Pozniak (UK)</i>
ES2CH	18.30–18.35	Welcome and introduction <i>Anton Pozniak (UK)</i>
ES2.1	18.35–18.50	A new era in the management of HIV-infected patients <i>Bernard Hirschel (Switzerland)</i>
ES2.2	18.50–19.10	Optimising treatment outcomes for treatment-experienced patients <i>Giovanni Di Perri (Italy)</i>
ES2.3	19.10–19.30	Providing treatment-naïve HIV-1-infected patients with optimal care <i>Hans-Jürgen Stellbrink (Germany)</i>
ES2.4	19.30–19.45	Looking to the future: expanding opportunities across the treatment spectrum <i>Christine Katlama (France)</i>
	19.45–20.00	Panel discussion
ES2CH	20.00	Closing remarks <i>Anton Pozniak (UK)</i>



SCIENTIFIC PROGRAMME (continued)

WEDNESDAY 12 NOVEMBER

O31	08.30–10.10	'Non-AIDS Morbidities': Part of Life, HIV Disease and/or Adverse Events of Therapy
O31CH		<i>Chairs: David Cooper (Australia) Ray Fox (UK)</i>
O311	08.30–08.50	Pathogenesis of non-AIDS morbidities in HIV disease and implications for management <i>Steven Deeks (USA)</i>
O312	08.50–09.10	Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors <i>Jens Lundgren (Denmark)</i>
O313	09.10–09.25	Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH): myocardial infarction and abacavir use <i>Justyna Kowalska (Denmark)</i>
O314	09.25–09.40	Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study group <i>Kathy Petoumenos (Australia)</i>
	09.40–10.10	Panel discussion
	10.10–10.40	COFFEE
O32	10.40–12.15	Cancer, Bone and Renal Disease
O32CH		<i>Chairs: William Powderly (Ireland) Rainer Weber (Switzerland)</i>
O321	10.40–11.00	HIV, immune deficiency and malignancy <i>Andrew Grulich (Australia)</i>
O322	11.00–11.20	Bone disease and HIV: together for the long term <i>Patrick Mallon (Ireland)</i>
O323	11.20–11.35	High HIV viral load inhibits osteoblast function and signalling <i>Nicholas Chew (Ireland)</i>
O324	11.35–11.55	Management of renal disease in HIV infection for the HIV physician <i>Ian Williams (UK)</i>
	11.55–12.15	Panel discussion
	12.15–13.45	LUNCH AND POSTERS (including Poster Discussion Sessions)
Hall 4, Room 1	12.30–13.30	HIV-related Infections, Co-infections and Cancers: Hepatitis Co-infection (HCV and HBV)
PCH		<i>Chairs: NM Samuel (India) Mauro Schechter (Brazil)</i>
P134		Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH Cohort <i>Ramon Teira (Spain)</i>

SCIENTIFIC PROGRAMME (continued)

- P135 **Screening for liver fibrosis in HIV-mono-infected patients with increased ALT comparing FibroScan with FIB-4**
Stefan Mauss (Denmark)
- P264 **Cross-sectional study to determine prevalence of significant liver fibrosis (F2-F4) in HIV/HCV co-infected patients: GRAFIHCO study**
Angel Burgos (Spain)
- P265 **A 4-year follow-up of a cohort of HIV-positive cirrhotic patients**
Paula Tuma (Spain)
- P266 **Rapid virological response is the best predictor for achieving SVR under peg-IFN/ribavirin hepatitis C therapy in HIV/HCV co-infected patients**
Jürgen Rockstroh (Germany)
- P267 **Switching from zidovudine/lamivudine (ZDV/LMV) to tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/LMV) in HIV/HCV co-infection (COTKI study)**
Paola Nasta (Italy)
- P268 **HCV relapse after peg-interferon (IFN) plus ribavirin (RBV) therapy: is 12-week follow-up enough to determine sustained HCV clearance?**
Jose Medrano (Spain)

Hall 4, Room 1 12.30–13.30 **Laboratory Monitoring of Disease and Therapy**

- PCH **Chairs: Saye Khoo (UK)**
Veronica Miller (USA)
- P178 **Re-evaluation of resistance algorithms for lopinavir/ritonavir in the TITAN trial**
Vincent Calvez (France)
- P197 **Validation of an enhanced sensitivity Trofile™ HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5**
Jacqueline Reeves (USA)
- P198 **Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected with Clade C virus**
Sybil Eng (USA)
- P199 **Therapeutic drug monitoring of new formulation Kaletra in pregnancy**
Laura Else (UK)
- P241 **Modelling the change in lopinavir apparent oral clearance over time following cessation of lopinavir/ritonavir: data from the TAIL study**
Laura Dickinson (UK)



SCIENTIFIC PROGRAMME (continued)

O33	13.45–15.00	Important Recent Findings from Cohort Studies
O33CH		<i>Chairs: Cristina Mussini (Italy) Jeff Nadler (USA)</i>
O331	13.45–14.00	Patterns of viral suppression on cART as predictors of uncontrolled viraemia after starting a new antiretroviral after 1 January 2003 <i>Joanne Reekie (UK)</i>
O332	14.00–14.15	Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients <i>Wendy Bannister (UK)</i>
O333	14.15–14.30	Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART) <i>Colette Smith (UK)</i>
	14.30–15.00	Panel discussion
CS2	15.00–16.30	Update on the Clinical Management of Complex HIV/AIDS Cases: Interactive Session held in collaboration with IAS-USA
CS2CH		<i>Chairs: Roy Gulick (USA) Ian Williams (UK)</i> <i>Panel: Judith Currier (USA) Cristina Mussini (Italy)</i>
		Cases
CS2.1		• Strategies for antiretroviral therapy <i>Roy Gulick (USA)</i>
CS2.2		• Co-morbidities and complications that impact antiretroviral decisions <i>Ian Williams (UK)</i>
CS2.3		• Current issues in viral hepatitis co-infection with HIV <i>Jürgen Rockstroh (Germany)</i>
	16.30–17.00	COFFEE
SS6	17.00–18.30	Satellite Symposium: Gilead Sciences Europe Ltd Understanding and overcoming the challenges of late presentation of HIV patients
SS6CH		<i>Chair: Jürgen Rockstroh (Germany)</i>
SS6CH	17.00–17.10	Welcome <i>Jürgen Rockstroh (Germany)</i>
SS6.1	17.10–17.30	The epidemiology of late presentation in HIV <i>Caroline Sabin (UK)</i>
SS6.2	17.30–17.45	Strategies to encourage earlier presentation and diagnosis: The European experience <i>Antonio Antela (Spain)</i>
SS6.3	17.45–18.00	Strategies to encourage earlier presentation and diagnosis: The US experience <i>Yvette Calderon (USA)</i>
SS6.4	18.00–18.20	Current and emerging treatment approaches for late-presenting patients <i>Patrick Mallon (Ireland)</i>

SCIENTIFIC PROGRAMME (continued)

SS6CH 18.20-18.30 **Summary and close**
Jürgen Rockstroh (Germany)

18.30-20.00 **POSTER RECEPTION**

THURSDAY 13 NOVEMBER

O41 08.30-10.00 **Hot Topics and Late Breakers 1**

O41CH *Chairs: Eric Sandström (Switzerland)*
Schlomo Staszewski (Germany)

O411 08.30-08.50 **HIV-TB co-infection and TB drug resistance: an emerging threat to HIV and TB programmes**
Gerald Friedland (USA)

O412 08.50-09.05 **Factors associated with poor clinical outcome among HIV-infected patients with TB in Europe and Argentina. The HIV/TB collaborative study**
Daria Podlekareva (Denmark)

O413 09.05-09.20 **Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naïve HIV-1 infected adults**
Thomas Kakuda (USA)

O414 09.20-09.35 **48-week data from Study AVX-201: a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance**
Susan Cox (Australia)

O415 09.35-09.50 **Efficacy and safety of 48-week maintenance with OD ATV vs. ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: Study AI424136**
Santiago Moreno (Spain)

09.50-10.00 **Panel discussion**

10.00-10.30 **COFFEE**

O42 10.30-12.05 **Hot Topics and Late Breakers 2**

O42CH *Chairs: José Gatell (Spain)*
Ian Weller (UK)

O421 10.30-10.50 **When to start therapy? The patient's viewpoint**
Gus Cairns (UK)

O422 10.50-11.05 **Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load suppression for a year on HAART?**
Laura Waters (UK)

O423 11.05-11.20 **Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohort**
Alexander Zoufaly (Germany)

O424 11.20-11.35 **Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients**
Sandra De Meyer (Belgium)



SCIENTIFIC PROGRAMME (continued)

O425	11.35–11.50	Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of MOTIVATE 1 and 2 studies <i>David Hardy (USA)</i>
	11.50–12.05	Panel discussion
	12.05–12.15	Closing Remarks
	12.05–12.10	Closing comments from the EATG representative <i>Wim Vandeveldel (Portugal)</i>
	12.10–12.15	Closing comments from the Congress Chairperson <i>Ian Weller (UK)</i>
	12.15–13.00	LUNCH AND CLOSE OF CONGRESS

KEYNOTE LECTURERS

We are delighted to have secured contributions from the following internationally renowned individuals and hope that the information below will be of interest in relation to the Keynote Lecture session on Sunday evening following the Official Opening.

Christine Katlama, Professor of Infectious Diseases and Head of the AIDS Clinical Research Unit, Pitié-Salpêtrière Hospital, Paris, France



Christine Katlama has worked in the field of HIV since 1982 and was involved in the discovery of HIV-2 in 1986. Her group first demonstrated the impact of HAART on immune reconstitution and works extensively in the field of new drugs and resistance.

Professor Katlama is a founder member of ORVACS, which is developing a therapeutic vaccination programme for HIV-infected patients. As a founder and President of Solthis (Solidarité Thérapeutique & Initiatives Contre Le SIDA), a non-governmental organisation, she is also heavily involved in access to HIV treatment and education in developing countries.

Professor Katlama was President of the European AIDS Clinical Society until July 2004, and remains an active member, involved in many educational initiatives. She is a member of the editorial boards of several journals, including *HIV Medicine* and *AIDS*.

AUTHOR INDEX

Name	Activity	Name	Activity	Name	Activity
Aarons, L	P241	Antinori, A	P3*, P166, P169, P179, P292	Barros, C	P173
Abad, F	P162	Antinori, S	P274	Barrufet, P	P92
Abdalla Elteer, A	P214	Antoniadou, A	P186, P294	Basilico, C	P234
Abdel-Kader, L	P141	Antonopoulou, S	P105	Bassaris, H	P124
Abdon, A	P78	Apostolova, N	P120, P161*	Bastos, R	P288
Abrescia, N	P3	Aquilina, C	P29	Battegay, M	CS1CH
Absalon, J	P8, P136*	Arama, V	P255	Batuca, J	P96
Abu Bakar, M	P305*	Arastéh, K	P24	Baumgardt, C	P32
Acinapura, R	P166	Arazo, P	P64	Baumgarten, A	P7, P75
Ackad, N	P81	Arbune, M	P261*	Baxter, J	P190, P192*
Adesola, O	P172	Arechavala, A	P252	Beauvoit, B	P147, P148
Adeyemi, A	P172*	Arildsen, H	P90	Becker, E	P304*
Adorni, F	P34	Arranz, J	P53	Beckerman, K	O221*
Adorni, FA	P194	Arredondo, M	P20	Bedimo, R	P9*
Aggett, S	P229*	Arribas, J	P44, P64, P308	Beets, G	P23, P27
Agostinone, A	P152	Arumainayagam, J	P15	Beghetto, B	P115, P156, P300
Agud Aparicio, J	P93, P100, P173	Asghar, A	P248*	Behrens, G	SS4.2
Aguirrebengoa, K	P33	Ashby, J	P260	Beijnen, J	P242
Ahmed, N	P227	Aster, V	P295*	Belaebi, L	P46
Ahmed, S	P79	Avidor, B	P188	Belda, A	P162
Aich, B	P193	Avihingsanon, A	P244*	Bele, V	P193
Airoidi, M	O213, P167	Awni, W	P95, P101, P245, P247	Belfiori, B	P84
Álamo del Rodríguez, M	P93	Awunor, C	P149	Bellagamba, R	P292
Alas, B	P68	Ayala, E	P288	Bellido, R	P142
Albalate, M	P128	Ayoub, A	P154*	Bellistri, G	P1, P88, P97
Alcalde-Encinas, M	P164, P254	Azijn, H	P181, P189	Bellos, N	P21
Alcaez, C	P33	Babu, C	P79	Benea, O	P255, P261
Alcorn, K	O421	Back, D	O121, O12CH, P6, P233, P237, P238, P250	Benetucci, J	P252
Alessandra M. Martino, A	P214	Badal-Faesén, S	P198	Bengleil, AS	P214
Ali S. Bengleil, A	P214	Bai, F	P1, P88, P97, P167	Beniowski, M	O331
Allavena, C	P26*	Baietta, L	P233	Berenguer, J	P54
Allegri, G	P313	Bailey, A	P260, P262*	Berg, J	P315
Almasi, F	P46*, P287*	Bailey, M	P297	Berg, T	P201
Almeida, I	P51	Baily, G	P203	Berger, F	P135, P160
Almeida, J	P288	Bakoyiannis, G	P124	Bergin, C	P132, P155, P276, P293
Aloisi, M	P177	Balcarek, K	P147	Bergman, J	P222
Alonso, P	P288	Baldelli, F	P10, P84, P118	Bernardi, S	P213
Altclas, J	O414	Balestra, P	P292	Bernasconi De Luca, D	P234
Alterio, L	P152	Balle, N	P174	Bernstein, B	P95, P101, P110, P245, P247
Altice, F	P240	Ballesteros, D	P120, P161	Berry, A	P249
Álvarez, Á	P89	Ballestri, S	P139, P140	Bertheau, P	P269
Álvarez, M	P54, P78	Balogh, A	O415	Bhatti, L	P190, P192
Ambar, R	P196, P209	Bambumba, A	P79	Biagetti, C	P123
A-Megido, J	P290	Bandivdekar, A	P211	Bickel, M	P18*, P32, P59*, P122
Amiramini, S	P212	Bánhegyi, D	P22	Bigoloni, A	P45
Ammari IME	P214	Bannister, W	O332*	Bijuklic, K	P200
Ammassari, A	P3, P166	Barassi, A	P235	Billing, N	P98*
Amoroso, A	P121	Barda, B	P202	Bini, T	O213, P88, P153, P167, P235
An der Heiden, M	O423	Barker, R	P262	Bino, S	P87
Ancok, B	P116*	Barlow, P	P289	Biondi, M	P235
Andersen, T	P90	Barranger, E	P222	Bisi, L	P167, P273
Anderson, J	O422, P73*, P203	Barreiro, P	P128, P137, P138, P265, P268, P284, P286	Bisicchia, F	P17
Andrade, M	P89	Barrieshee, A	P278*	Bisimba, J	P175*
Andreoni, M	P3, P56	Barrios, A	P173, P251	Bissé, E	P210
Andrews, L	P240			Bissio, E	P317*
Angeletti, G	P118				
Anghel, N	P257				
Antela, A	SS6.2, P44				

*Indicates presenting author.



AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Blanc, C	P38	Buxton, G	P107*	Castro Lopez, H	P104*, P108*
Blanco, F	P20*, P42, P66, P128, P137*	Buzon, M	P50	Cattelan, A	P56
Blanco, JL	P64	Byakwaga, H	P70*	Cauda, R	P99, P243
Blanco JR	P64	Caballero, E	P40	Caum, C	P150
Blas-García, A	P120*, P161	Cabie, A	P26	Caumes, E	P269
Blaxhult, A	P82	Cabrero, E	P80, P117, P264, P308	Cavassini, M	P231
Bobrik, A	O134*	Caffagni, G	P140	Caylá, J	O412
Bodtlaender, A	P59	Cahn, P	O414, O13CH	Ceccherini-Silberstein, C	P35, P179
Boffito, M	P241	Cain, K	P259	Cecchini, D	P252*
Bogner, J	O212	Cairns, G	O421*	Celesia, B	P17*
Bolan, R	P303	Cairns, V	P41	Cervero, M	P173*
Bonfanti, P	P19, P74	Caixas, U	P96	Cervero Jiménez, M	P93*, P100*
Bonjoch, A	P50*, P150*	Calbi, M	P99	Cesari, M	P1, P274
Bonnet, J	P147, P148	Calcagno, A	P233	Chadwick, D	P107
Bonora, S	P233	Caldas, C	P296*	Chaikan, A	P237*
Boorman, H	P28	Calderon, Y	SS6.3	Chandramani, S	P15
Boothby, M	P113*	Callegaro, A	O213	Chanmano, S	P244
Borderi, M	P123*	Caluwaerts, S	P223	Charles, M	P229
Borghini, V	P273*	Calvez, V	P29, P178*	Charlotte, F	P269
Borras-Blasco, J	P162*	Calza, L	P165	Chaudhary, M	P310
Boschi, A	P30	Camacho, R	P51	Chauret, N	P298
Bossola, M	P177	Camanni, G	P10, P118*	Chein, M	P303
Bottecchia, M	P284	Cambrea, S	P226*	Cheng, A	P4
Bottiau, E	P270, P283*	Campbell, L	P260*	Chernai, N	P222
Bouzas, M	P252	Candido, V	P196	Chew, N	O323*, P109*
Bovee, I	P208	Canestri, A	P38*	Chiavaroli, R	P106, P131
Boven, K	P2*, P239	Cañizal, A	P252	Chierakul, N	P237
Bower, M	P14, P49, P116, P248	Cano-Sánchez, A	P164, P254	Chiesa, E	P206
Boyce, C	P121	Capasso, M	P39	Chiesi, A	O331
Boyd, K	O122	Capetti, A	P31*	Chilton, D	O112*
Boyd, M	P70	Caramma, I	P274	Chini, M	P47, P105
Boyle, N	P199	Carcaba, V	P290	Chiodo, F	P123
Bracciale, L	P168	Cardellach, F	P142, P143, P144, P146	Chiotan, C	P255
Bradbeer, C	P305	Cardoso, S	P296	Chirianni, A	P3
Branco, T	P96, P155	Carganico, A	P13, P25	Chiu, Y	P95
Brandolini, M	P56	Carini, E	P45	Chranioti, K	P294
Braun, P	P12, P43, P201	Carlebach, A	P18	Christensen, J	P90
Bravenboer, B	P55	Carocci, C	P69*	Christie, A	P315
Bravo, I	P65	Carosi, G	O415, P52, P267, P282	Chuah, J	P72
Bray, D	P206	Carradori, S	P74	Chuchuttaworn, C	P237
Breiden, J	P246	Carrilho, C	P288	Chui, Y	P245, P247
Brennan, M	P199, P246	Casado, J	P80*	Cicconi, P	P153, P235
Brenner, B	O114	Casana, M	P88, P97, P153*, P235*	Cingolani, A	P168
Brodth, H	P32	Casas, E	P65, P173	Ciraru-Vigneron, N	P222*
Brogan, A	P306, P309	Caseiro, M	P196, P209	Citton, R	P213
Brosa, M	P314	Casillas Rodriguez, J	P104, P108	Clark, D	P203*
Bruce, R	P240*	Cassetti, I	O414, P4	Clay, E	P303
Brun, F	P92	Castagna, A	P36, P37, P45, P202	Clerici, M	P206
Bruyand, M	O314, O412	Castaña, M	P141	Clermont, P	P298
Buelens, A	P239	Castera, M	P162	Clifford, D	O211*
Burapat, C	P259	Castilla, V	P251	Clotet, B	O331, P23, P33, P42, P50, P54, P58, P64, P65, P67, P114, P142, P150, P157, P171, P176, P191, P272*
Burger, D	P244	Castro, A	P42, P92	Clumeck, N	P23*, P48, P289
Burgos, A	P80, P117, P264*, P308			Coakley, E	P190, P197
Burk, M	P188			Cobos-Trigueros, N	P164, P254
Butler, K	O122				
Buvé, A	P223				

* Indicates presenting author.

AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Coelho, R	P296	Daniels, R	P14*	Di Giambenedetto, S	P168, P243
Coen, M	P206	d'Aquin Toni, T	O114	Di Masi, F	P152
Cohen, C	O214*, SS2.2, SS5.2, P157	Darbyshire, J	O12CH	Di Matteo, L	P152
Cohen, D	P110, P170	d'Arminio Monforte, A	O314, O332, O23CH, P1, P88, P97, P153, P235	Di Perri, G	ES2.2, P233
Cohen, K	O124	D'Arrigo, R	P35, P179	Di Vincenzo, P	P39, P194
Colafigli, M	P243	Das, A	P28	Diaz, M	P40
Colberg, K	P62	Das, S	P15*, P113	Diaz, R	P209
Colby, D	P77	Däumer, M	P201	Dickinson, L	P237, P241*
Colebunders, R	P228, P270	Davies, A	P91	Diderichsen, P	P245
Cognigni, G	P52, P282	Davies, G	P237	Dierynck, I	O424, P189
Colson, A	O214	Davis, C	P121*	Dietz, B	P307, P311, P312
Comi, L	P88, P97, P153, P235	D'Avolio, A	P233	Diniz, A	P51
Compagnucci, A	O222	de Barra, E	P132, P293	Doan, T	P95, P101
Compangocci, A	P46	de Béthune, M	O424, P189	Dobosz, S	P216*, P217
Comparini, R	P209	De Boer, M	P283	Doerholt, K	O122
Conner, C	P121, P240	de Gaetano Donati, K	P99*	Dolara, A	O213
Contés, E	P251	De Gennaro, M	P206	Domingo, P	ES1.3, P42, P53, P67, P134, P191
Conway, B	P81*, P277*, P278	de Guzmán, M	P251	Dominguez, K	O221
Cooper, C	P28	de la Calle, O	P314	Doran, P	O323
Cooper, D	O414, O31CH, P70, P244, P297	De la Torre, J	P65, P112	Dragsted, U	P6, P250
Cordes, C	P2	de Lazzari, E	P53	Dravid, A	P193
Córdoba, M	P20	De Longis, P	P169	Drechsler, H	P9
Coria Ramirez, E	P108	De Luca, A	P99, P168, P243	Duarte, N	P196
Corpolongo, A	P3	De Meyer, S	O424*, P21, P24, P181, P189	Dufty, N	P249
Corsi, C	P69	De Pablo-Bernal, C	P89	Duiculescu, D	P224, P275*
Corso, N	P133	De Paepe, E	O424	Dumitrescu, F	P257*
Cortés, C	P92	De Silvestri, A	P30	Duncan, A	P204
Cosín, J	P53, P78, P134	De Smedt, G	P23, P27, P189, P272	Duncan, F	P277
Cossarini, F	P202	De Socio, G	P19, P74	Dunlop, W	P310*
Costagliola, D	P299	De Terlizzi, F	P215	Duvivier, C	P26
Costarelli, S	P52	De Wit, S	O314, P36, P37, P48*, P289	Eberhard, A	P195
Cotter, E	O323	De Wolf, H	P205	Eberle, J	P200
Coulter-Smith, S	P199, P246	Deeks, S	O311*	Eberle, S	P86
Couto-Parada, X	P203	Degen, O	P62*	Ebrahimi, R	P61, P63
Covington, D	O221	Deig, E	P78, P146	Eccleston, K	P79*
Cox, S	O414*	DeJesus, E	O214, O413, P61, P63	Echeverría, P	P53, P65*, P67*, P150
Cozzi-Lepri, A	P183	del Álamo Rodríguez, M	P100	Edwards, C	P91
Crauwels, H	P239*	del Arco, A	P102	Edwards, I	O121
Crespo, M	P40	Delforge, M	P48, P289	Egle, A	P200
Cristina, M	P88	Delfraissy, J	O415	Egnell, K	P256
Cui, Y	P247	Delgado, C	P51	Ehret, R	P43
Cuko, G	P153	Delgado-Alves, J	P96	ELA Group*	P65
Cupsa, A	P257	Della Torre, L	P202	Elbasha, E	P310
Curran, A	P40, P54	Dellamonica, P	P26	Elion, R	O214
Currier, J	PCH	Deloof, A	P205*	Ellis, E	P219, P225
Curtin, J	P57	Delpech, V	O112	El-Sadr, W	O314
Cusato, M	P234	Demeester, R	P283	Else, L	P6, P199, P241, P246, P250*
Cuthbertson, Z	P6, P250	Demopoulos, C	P105	Elteer A	P214
Cuzin, L	P26	Deshpande, A	P211	Emery, S	P70, P297
Da Cunha, C	P22	Deveaud, C	P147, P148	Emmelkamp, J	P266, P304
Da Silva, B	P95, P101*, P110*, P245	DeWet, J	P81	Ene, L	P275
Daikos, G	P186	Di Biagio, A	P215	Enejosa, J	P4
D'Alessandro, M	P19	Di Castelnuovo, A	P99	Eng, S	P198*
D'Amico, R	P125, P139, P140			England, K	P218*

*Indicates presenting author.



AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
English, S	P103*	Friend-du Preez, N	P73	Giannaris, M	P124
Epting, T	P210	Friis-Møller, N	O313, O314	Gianotti, N	P3, P45
Eron, J	P27	Fumaz, C	P114, P171*, P176*	Giaquinto, C	O222
Esplugues, J	P89*, P120, P161	Furrer, H	O412	Gibb, D	O122, O125, O222*
Esposito, R	P34, P125, P273, P300	Fusetti, G	P45	Gibbons, S	O121, P199, P233, P246
Esser, S	P41*, P76*	Gagliani, L	P196, P209	Gibbs, S	P110
Estany, C	P150	Gaikwad, S	P193	Gibellini, D	P123
Estrada, V	P54	Galani, L	P294	Giffo, B	P29
Etzel, A	P4	Galindo, M	P134	Gilks, C	O125
Everhard, F	P306, P309	Gallagher, L	P277	Gilliam, B	P121
Evers, S	P163	Gallego, M	P102	Ginocchio, F	P215
		Galli, L	P45, P202	Giola, M	P234*
Fabbiani, M	P243*	Galli, M	P1, P39, P119, P194, P274	Girardi, E	O412
Fakoya, A	PCH	Gallo, C	P290	Gisolf, E	P55, P60
Falco, V	P40	Gallo, L	P12, P76	Giubelan, L	P257
Fang, W	P240	Garb, J	O214	Giulianelli, M	P169
Fantoni, M	P99	García, M	P33, P58	Giuntini, R	P74
Farajallah, A	P8, P61, P63	García, P	P146	Gizinska, J	P258
Fardel, V	P231	García Benaya, E	P93, P100	Goelz, J	P195
Farrell, G	P276	García Lacalle, C	P93, P100	Gogos, H	P124
Fätkenheuer, G	O425, P12, P157*, P195, P266	García-Alcalde, M	P134	Goikoetxea, J	P33
Fernandez, S	P112	García-Bujalance, L	P314	Goldbach, J	P41
Ferramosca, S	P39	García-García, J	P164, P254	Golegā, A	P209
Ferreira, A	P296	García-Henarejos, J	P42, P44, P164, P254	Gölz, J	P76
Ferreira, D	P296	García-Samaniego, J	P268, P284	Gómez-Sirvent, J	P221
Ferrer, E	P44, P53, P92	Gargalianos, P	P124, P186	Gómez-Sucerquia, L	P161
Ferrer, M	P114, P171, P176	Garrabou, G	P142*, P143, P144, P146*	Gonzalez, A	P130, P302
Ferrer, P	P54, P78	Garraffo, R	P26	González, M	P221
FHDH-ANRS 04, the	P299	Garren, K	P312	González, Y	P161
Filice, C	P119	Garrido, C	P20	Gonzalez-García, J	P264
Firlag-Burkacka, E	P184	Garrido, M	P134	González-Lahoz, J	P20, P128, P137
Fisher, M	O332, O422	Garvey, L	P301*	Gonzalez-Mena, A	P64
Fituri, OA	P214	Gascon, J	P288	González-Mestre, V	P114
Flaherty, J	P61, P63	Gaspar, G	P173, P251*	González-Pardo, G	P66
Flamm, J	P157	Gatell, J	O332, O42CH, SS4CH, P53*	Goodrich, J	O425, P154
Flandre, P	P26	Gathercole, L	P113	Gorčíková, J	P212
Fleming, C	P199	Gatti, F	P52*, P267, P282	Gori, A	P97, P167
Florence, E	P36*, P37, P228*, P270*, P283	Gazzard, B	SS2CH, SS2.1, PCH, P14, P16, P49, P116, P129, P151, P248	Gori, C	P35
Flores, J	P64	Geijo, P	P42, P92, P134	Gorowara, M	P244
Floyd, S	P11	Genoway, K	P277	Graf, B	P16*
Foggia, M	P3	Georgoulakis, J	P294	Grana, M	P102, P112
Fomundam, H	P73	Geretti, AM	SS4.3	Grancea, C	P182
Fontas, E	O314	Germano, I	P96	Granhholm, H	P82
Forbici, F	P179	Gersbacher, E	P195	Granier, C	P83
Force, L	P92	Gervasoni, C	P119	Grant, D	P110
Fortuny, C	P143, P144	G-Franco, A	P290	Grebely, J	P277
Fox, R	O31CH, P103, P219, P225, P253*, P291	Ghaji, N	P149	Green, H	O112, O222
Fox, S	P68	Ghanem, M	P15	Gregis, G	O213
Fox, Z	P183	Giamarellou, H	P124, P294	Greil, R	P200
Francisci, D	P10, P84*, P118	Giancola, M	P166, P169	Griffa, L	P80, P117*, P264
Francque, S	P270, P283	Gianelli, E	P74	Grima, P	P106, P131
Fraser, C	P277			Grima, PF	P106*, P131*
Fredrick, L	P110			Grimm, K	P63
Freedberg, K	O113			Grinsztejn, B	P21, P24
Friedland, G	O411*, P240			Grisaru, G	P188
				Groeneveld, P	P55
				Grossi, P	P234

*Indicates presenting author.

AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Grosskurth, H	P11	Hill, A	P5*, P36, P37, P127, P178, P181	Jensen, J	O214
Grosso, C	P74	Hirschel, B	CoS.2, ES2.1	Jimenez, I	P268
Grolich, A	O321*	HIV/TB Study Group	O412	Jiménez-Nácher, I	P66
Guaraldi, G	P34*, P94*, P115, P125*, P139*, P140*, P156, P177, P300*	Hjelmgren, J	P313	Johnson, M	O333, O21CH, P6, P23, P83, P250
Guatelli, K	P196	Hodder, S	P63*	Judd, A	O122
Guelar, A	P130, P302*	Hoepelman, A	P60	Jullien, V	P287
Guevara, F	P20	Hoepelman, I	P55	Jusdado, J	P251
Guiget, M	P269	Hoetelmans, R	P239	Jusdado Ruiz-Capillas, J	P93, P100
Gulick, R	O425, CS2.1, CS2CH	Höhn, C	P43		
Gulizia, R	P119*	Høj, L	O313, P183		
Gupta, A	P16	Hojman, M	P227*	Kabeya, K	P48
Gupta, N	P158	Holas, C	P95	Kachman, E	P188
Gupte, N	P193	Holm, S	P71	Kaiser, R	P201
Gussio, M	P17	Holmes, P	P14, P248	Kakuda, T	O413*, P272
Gute, P	P18, P32	Holodniy, M	P9	Kalath, T	P257
Gutierrez, F	P53	Horban, A	PCH, P184	Kambraki, M	P214
Gutierrez, M	P67	Hornberger, J	P318	Kanjavanit, S	O222
Gyllensten, K	P82*	Hosein, S	CoSCH	Karafoulidou, A	P47, P186
		Hosseina, M	P277	Karaiskos, I	P294
		Hristea, A	P255	Karakitsos, P	P294
Haas, B	P83	Huang, W	P197	Kasteren, M	P55
Habel, A	O214	Hughes, P	P11	Katabira, E	O131*
Haberl, A	P32, P71*, P76	Huitema, A	P242	Katlama, C	KL2*, SS2.3, ES2.4, P21*, P22*, P26, P38, P269, P272
Haigney, Z	O413	Hull, M	P271*		
Hain, J	P86*	Husstedt, I	P163*	Katsarolis, I	P294
Haine, D	P81	Hutt, E	P306*, P309*	Kavatha, D	P294
Hairrell, J	P110			Kawiya, J	O125
Hakim, J	O132*	Iacoviello, L	P99	Kedem, E	P188
Hamlyn, E	P260	Iannotti, N	P99	Kelleher, A	P297
Hamouda, O	O423	Ibrahim, F	P262	Kelly, S	P132*
Han, D	P197	Idris El Ammari, I	P214	Kerndt, P	P303
Hanhoff, N	P71	Ilie, M	P226	Kerr, S	P244
Hankins, C	CoS.1	Imaz, A	P40*	Kestens, D	P239
Hanna, G	P185	Ionescu, C	P275	Khanna, M	P158
Hanzlíková, J	P212	Iosipenco, M	P255	Khatib, N	P49
Hardy, WD	O425*	Iribarren, J	P33, P221, P314	Khaykin, P	P32, P122
Harris, M	P271	Isaacs, R	P207	Khoo, S	O121*, O123*, O125, PCH, P6, P199, P233, P237, P238, P241, P246, P250
Harrison, L	O112	Isenman, H	P248		
Hartkoorn, R	P238	Ive, P	O124, P2	Kiely, B	P293
Hartmans, N	P208	Iwuala, S	P126*	Kieran, J	P246, P276*
Harxhi, A	P87*	Izopet, J	P26	Kigen, G	O121
Hassoun, G	P188			Kim, D	P247
Hatz, C	CS1.5	Jackson, A	P276	Kimaiyo, S	O121
Hatzakis, A	P47, P186	Jackson, AGA	P129, P151	Kinder, F	O214
Haubrich, R	P27*, P312	Jackson, F	P83	Kint, I	P223*, P228
Hay, P	P6, P250	Jackson, V	P199*, P246	Kirk, O	O212, O313, O332, O412
Heera, J	O425	Jadhav, S	P211*	Kirschner, J	P147, P148
Hegener, P	P135, P160	Jaegel-Guedes, E	P195	Kiss, L	P197
Hemmett, L	P313	Jaeger, H	P7, P13, P25, P41, P75, P195	Kitas, G	SS3.3
Henke, J	P135, P160	Jaffe, H	O224*	Kittikraisak, W	P259
Hennessy, M	P91, P236	Jan, E	P91	Kityo, C	O125*
Hepburn, M	P219, P225	Janke, M	P266	Kjær, J	P183*
Hernandez-Quero, J	P42, P64	Jansen, K	P272	Klauke, S	P12, P18, P32, P59
Herrero-Segastume, V	P164, P254	Jarrin, I	P279	Klein, C	P95*, P101, P245, P247
Hertling, S	P62	Jauer, M	P200		
Hervás, R	P173	Jayasuriya, A	P249		
Hervey, C	P207				

*Indicates presenting author.



AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Knecht, G	P13, P25, P59, P122	Lázaro, P	P308	Lyll, H	O122, O223*, O222, O22CH
Knechten, H	P12, P13*, P25, P43*, P195	Lazzarin, A	O415, P21, P45, P76, P202, P272	Lynen, L	P283
Knight, E	P277	Lazzaroni, L	P234	Lyons, F	P293
Knobel, H	P53, P130, P302	Lebrecht, D	P145, P147, P148	Maa, J	P8, P61, P63
Koegl, C	P75*	Ledergerber, B	O212, O331	MacConnachie, A	P103, P219, P225, P253, P291
Koeppe, S	P25	Lee, A	P203	Machala, L	O331, P295
Kok, P	P263	Lee, V	P79	Macias, J	P141*
Kollan, C	O423	Leen, C	P315	Mackie, K	P204
Komninakis, S	P196, P209	Lefebvre, E	P157	Mackintosh, C	P253
Konig, J	P295	Lefevre, V	P222	MacPherson, P	CoS.3
Konopnicki, D	P289*	Legrand, J	P55	MacRae, K	P297
Kontos, A	P85	Lekander, I	P315*	Mactier, H	P219, P225
Koole, O	P228	Leleu, G	O415	Madeddu, G	P19, P74
Koopmans, P	P55	Lennemann, T	P122	Madejon, A	P284
Körber, A	P76	Leoncini, L	P69	Madruga, J	P4*
Kordosis, T	P85*, P186	Letang, E	CS1.3, P288*	Maes, P	P223
Kourkoudi, S	P124	Levy, Y	SS1.3	Magafas, N	P124
Kovacs, C	P81	Leyes, M	P221	Magenta, A	P153
Kowalska, J	O313*	Li, J	P101	Maggiolo, F	O213*, P3, P167*
Kraemer, S	P29	Libertone, R	P292	Magiorkinis, E	P47, P186
Kraja, D	P87	Lim, P	P72	Magiorkinis, G	P47, P186
Kreuzberg, C	O423	Limb, S	P203	Magnier, J	P279
Krivine, A	P46	Lin, S	P240	Mahungu, T	P238
Ktorza, N	P38	Lin, Y	P101	Mahungu, TW	P6*, P250
Kumar, R	P72, P310	Lins-Filho, A	P209	Maida, I	P138*, P286
Kumarasamy, N	P72, P111	Liška, M	P212	Mair, R	P229
Kumari, B	P15	Liuzzi, G	P292*	Majluf Cruz, A	P104, P108
Kuritzkes, D	O115*	Llibre, J	P42*, P50, P58, P191	Makne, A	P193
Kurowski, M	P59	Lo Caputo, S	P35*, P206	Malashenkov, E	O412
Kwan, W	P238	Lo Cicero, M	P39	Maldonado, M	P227
		Lobo, J	P290*	Malincarne, L	P10*
		Loeschel, E	P83	Mallal, S	PCH
La Rosa, R	P17	Logue, K	P81	Mallolas, J	P53
Labarga, P	P128*, P137, P265, P268	Lonardo, A	P139, P140	Mallon, P	O322*, SS6.4
Lacombe, K	O212	Longo, N	P81	Mallon, PW	P70
Lafuente-Lafuente, C	P279	Lopardo, G	P317	Maltez, F	P51
Laird, J	P291	López, R	P65	Manata, M	P51
Lalezari, J	O413	López-Aldeguer, J	P134, P221	Mancini, M	P136, P180
Lallemant, M	O222	Lopez-Bernaldo de Quiros, J	P64	Manconi, P	P133
Lambert, J	P109, P199, P246*	López-Blázquez, R	P142	Mandalia, S	P129, P151
Lampe, F	O333	López Gomez, M	P44	Manfredi, R	P165*
Lampreia, F	P96	Lorenzini, P	P3, P169, P179	Mangafas, N	P105
Lane, HC	KL2*	Loria, P	P139, P140	Manigart, Y	P289
Larrouse, M	P54	Losina, E	O113	Manolescu, L	P182*
Larson, J	P197	Losso, M	O414	Manonelles, G	P227
Lascoux-Combe, C	P299	Loutfy, M	P318	Mansinho, K	P51
Lataillade, M	P180*, P185	Loy, A	CS1.1	Manzini, L	P273
Latarska-Smuga, D	P258	Loyo, K	P124	Manzoli, L	P19
Laterreur, J	P298	Lozano, F	P134	Marasca, G	P168
Lathouwers, E	O424	Luechters, G	P266	Marcas, C	P226
Lattanzi, A	P94	Luminos, M	P255	Marcelin, A	P178
Lattimore, S	O112	Lundgren, J	O212, O312*, O313, O314, O331, O332, O412, P183	Marchetti, G	P1, P88*, P97
Lauriola, M	P206			Marconi, P	P74, P166, P179
Laursen, T	P174	Lutwana, F	O125	Marcotullio, S	PCH
Law, M	O314	Lutz, T	P12, P13, P25, P59, P122	Marczyńska, M	O222, P216, P217*
Lazanas, MC	P47, P105, P186				
Lazanas, ML	P124				

*Indicates presenting author.

AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Mardarescu, M	P255	Menichetti, S	P292	Moreno, S	O415*, SS1CH
Marinescu, P	P182	Menson, E	O122	Moreno, V	P128, P286
Mariño, A	P92	Menzaghi, B	P74*	Mørn, B	P90
Marks, S	P36, P37	Meraviglia, P	P31	Moroni, M	P1, P39
Marques, R	P51, P296	Merli, S	P31	Morreel, S	P228
Márquez, M	P141	Merlini, E	P88, P97	Morris, J	P247
Marsh, T	P110, P170	Meroni, L	P1	Moshkovich, G	P285
Martin, S	P316	Merritet, J	P287	Mosthaf, F	P13, P25
Martin-Carbonero, L	P128, P137, P138, P265, P268	Metallidis, S	P124*	Mosti, S	P166
Martinelli, C	O213, P74	Miarka, M	P258*	Mota, M	P51
Martinelli, M	P69	Micheli, V	P31	Mounzer, K	P63
Martínez, E	SS3.2, P33, P54	Michielsens, P	P283	Mourtzoukos, S	P85
Martínez, V	P269*	Mihailescu, R	P255*	Moye, J	O222
Martínez-Madrid, O	P164, P254	Miuro, G	P11*	Moyle, G	SS1.2, P98, P129, P151, P241
Martinez-Picado, J	P50	Milazzo, L	P274*	Mueller, A	P18
Martino, A	P213	Miller, E	P57	Mueller, K	P148
Martino, AM	P214	Miller, M	P207	Mueller, M	P25
Martins, M	O414	Miller, R	O412	Mughini, M	P17
Mary-Krause, M	P299*	Miller, V	PCH	Mukhopadhaya, P	P193
Marzocchetti, A	P99	Mills, E	P28	Mulcahy, F	PCH, P76, P91, P236, P276
Maserati, R	P56*, P206*	Minaeva, S	P285*	Mulder, J	P242
Masini, G	P84	Minguez, C	P92	Muldoon, E	P263*
Mastronardi, M	P69	Miralles, C	P191	Müller, H	P201
Mateo, G	P67	Miralles, P	P221	Müller, K	P145
Matias, R	P209	Miranda, A	P51*	Munderi, P	O125, P11
Matos, N	P188	Miranda, C	P142	Muñoz, J	P33
Matti, A	P52, P267, P282	Miro, J	O412, P288	Muñoz, L	P141
Mauss, S	P12, P41, P135*, P160*, P195	Miró, Ò	P142, P143, P144, P146	Muñoz-Moreno, J	P114*, P171, P176
Mavilla, S	P17	Mocroft, A	O212*, O313, O331, O332, O412	Muñoz-Sanchez, P	P134
Mayer, H	O425, P154	Modena, M	P94	Muñoz-Sanz, A	P134
Mayer, K	P111	Moeremans, K	P313	Munteanu, D	P255
Mayr, C	P13, P25, P195	Moerman, F	P283	Mura, M	P19
Mazeron, M	P222, P279	Mofenson, L	O222	Murano, F	P227
Mazeu, I	P156, P177	Moisi, D	O114	Murray, J	P70
Mazza, F	P31	Mokhtari, Z	P269	Murri, R	P168*, P177
Mazzocato, V	P168	Mokoka, M	P263	Murungi, A	P204, P230*
Mazzotta, E	P19, P152	Molangeli, S	P85	Muscatello, A	P168
Mazzotta, F	P35	Molina, E	P144	Mussini, C	O33CH, P3, P167, P273
McCarthy, K	P259	Molina, J	P2, P24, P269	Mustafa Kambraki, M	P214*
McColl, D	P61	Moll, A	P41	Muyldermans, G	P187, P205
McConkey, S	P109	Moltó, J	P58, P67, P171, P176	Myer, L	P159
McDonough, M	P190, P192	Monia, M	P282	Nadal, D	O222
McGee, K	P113	Monleón, D	P120	Nadler, J	PCH
McGrath, D	P8, P136, P180, P185	Monpoux, F	O222	Nahon, N	P209
McKenna, P	P205, P208	Montaner, J	O135*, P271	Nakubulwa, S	P11
McNally, C	P263, P276, P293	Monteiro, E	P96	Nalumenya, R	O125
Meadway, J	P28	Montero, M	P130	Nandwani, R	P103, P219, P225, P253
Medrano, J	P128, P265, P268*, P284	Montessori, V	P271	Naniche, D	P288
Meleddu, R	P133	Moody, D	P240	Narciso, P	P179
Melero, J	P251	Mora, M	P64*	Nardini, G	P56, P115, P156, P300
Melza d'Eril, G	P235	Mora, N	P213	Nasta, P	P52, P267*, P282*
Mendez, J	P51	Morales, J	P120	Naubutu, J	P175
Méndez, I	P308*	Morales-Ramirez, J	P61		
Menendez, C	P288	Morán, A	P161		
		Morello, J	P20, P66*		
		Morén, C	P142, P143*, P144*, P146		

*Indicates presenting author.



AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Navarra, P	P243	Ortí, A	P92	Pett, S	P297*
Navarro, C	P64	Ortu, F	P133*	Peytavin, G	P29, P38
Naylor, C	P110, P170	Ortu, M	P119	Phanuphak, N	P232, P259
Necsoi, C	P48	Ortu, MO	P194*	Phanuphak, P	P72*, P232, P244, P259
Negredo, E	P50, P54, P65, P67, P114, P142, P150	Osiyemi, O	O413	Phillips, A	O212, O333, PCH
Negrón, R	P252	Otelea, D	P255	Phositlimakul, S	P259
Nelson, M	O425, SS1CH, SS5.1, P14, P16, P49, P98, P116, P127*, P230, P248, P315	Oteo, J	P44	Pialoux, G	O415, P157
Neumann, J	P145	Owen, A	O121, P233, P237, P238*	Piano, P	P133
Ng, J	P245*, P247*	Pacei, M	P206	Picchio, G	O424, P181, P189
Ngo-Giang-Huong, N	O222	Padiwongpaisarn, W	P232	Pich, J	P53
Nguyen, B	P207	Palacios, R	P102*, P112*	Pieri, A	P152
Nhassone, D	P288	Palella, F	P300	Pierone, G	O214
Nhat Vinh, D	P77	Palermo, F	P17	Pierotti, P	P35
Nicolàs, M	P142, P143, P144, P146	Palma, P	P213	Pierre, N	P29
Niculescu, I	P257	Palvarini, L	P74	Pierro, P	P166, P169
Nielsen, H	P90	Panagiotidis, J	P294	Pietrogrande, L	P153
Nieto Cisneros, L	P104, P108	Panagopoulos, P	P294	Piliero, P	P121, P190*, P192, P240
Nieves, D	P314*	Panagopoulos, PP	P124	Pillay, D	O111*, O112
Nikolaidis, P	P124	Pankam, T	P259	Pineda, J	P141, P264
Noah, C	P62, P201	Panteleev, A	O412	Pinta, A	P29
Noble, H	P203	Panzner, P	P212	Pippi, R	P118
Noertersheuser, P	P95, P101	Papadopoulos, A	P294	Pitt, J	P159*
Noguera, A	P143, P144	Paparizos, V	P47, P186	Podlasin, R	P258
Norton, M	P80, P308	Papili, R	P10, P84	Podlekareva, D	O412*, P6, P250
Nozza, S	P45*, P202*	Paraschiv, S	P255	Podsadecki, T	P170*, P247
Nuzzo, A	P94	Paraskevis, D	P47*, P186*	Podzamczar, D	P53, P92*
O'Connor, E	P199	Parkin, N	P197	Poizot, I	P26
O'Shea, D	P276	Parodi, A	P215	Pokrovsky, V	O415
Oldakowska, A	P216, P217	Parruti, G	P19*, P152*	Pol, S	O231*
Obbo, J	P28	Pascual-Pareja, J	P221	Polilli, E	P19, P152
Obel, N	O412	Pasley, M	P9	Pollack, S	P188
Obermeier, M	P200	Pasquau, J	P65, P78, P141	Polsonetti, B	O413
Obermeier, MJ	P201*	Pateri, F	P235	Pontrelli, G	P213*
Ocampo, A	P42, P221	Patsch, W	P200	Popielska, J	P217
Ocana, I	P40	Pattery, T	P187*, P205, P208*	Portilla, J	P141
Oelker-Grueneberg, U	P163	Patton, V	P219*, P225*	Portu, J	P33
Olaogun, O	P172	Pearce, H	P83, P155	Post, F	O412, P260, P262
Oldakowska, A	P217	Pedicelli, A	P99	Poulakou, G	P294
Oliver, A	P203	Pedrol, E	P78*, P134, P146	Powderly, W	O323, O32CH, P109
Olivetti, M	P97	Peeters, M	P23, P27, P181*, P189	Pozniak, A	ES2CH, P21, P24*, P241
Olupot-Olupot, P	P28*	Pelgrom, J	P223	Pradier, C	O331
Omran Al Futuri, O	P214	Pellegrin, I	P29	Prieto, M	P227
Oñate, F	P102	Pellicanò, G	P74	Prins, J	P155*
Oprea, C	P224*	Peltzer, K	P73	Prisca, A	P296
Orani, A	P56	Peña, J	P221*	Prosperi, M	P243
Orchi, N	P169	Penco, G	P74	Protopas, K	P294*
Orihuela, F	P112, P141	Pereira, S	P96*	Proulx, L	P298*
Orkín, C	P203	Perez, N	P33, P58	Przybylska-Stengiel, K	P184
Orlando, G	P34, P94, P115, P125, P139, P140, P156*, P177, P300	Pérez-Álvarez, N	P50, P67, P114, P142, P171, P176, P191	Puerta, S	P112
Orofino, G	P74, P167	Pérez-Escolano, I	P314	Pugliese, P	P26
Orrell, C	O113*, O124*	Pérez-Pagán, C	P164, P254	Puig, J	P50, P67, P114, P142, P150
Ortega, E	P264	Perniciaro, A	P68	Puig, T	P65
		Perno, C	SS3.1, P3, P35, P179	Pujari, S	P72, P193*
		Petoumenos, K	O314*, P70		
		Petropoulos, C	P197		

* Indicates presenting author.

AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Pulido, F	P54, P308	Roca, V	P53	Sahm, L	P132
Puoti, M	O233*	Rocha, M	P120	Saidi, Y	O222
		Rocha, S	P296	Sakka, V	P294
Quinzan, P	O213	Rochira, V	P140	Salami, O	P149*
Quirino, T	P19, P74	Rock, C	P293*	Salmon, D	P46, P287
		Rockstroh, J	CS2.3, SS1.1, SS5.3, SS5CH, SS6CH, P195, P207*, P266*, P304	Salpietro, S	P45
Rabelato, J	P209	Rodan, J	P112	Salvatori, M	P292
Rachlis, A	P22	Rode, R	P170	Samarawickrama, A	P260, P262
Radoi, R	P224	Rodkjaer, L	P174*	Sambatakou, H	P47, P124, P186
Radulescu, M	P255	Rodrigues-Matias, R	P196*	Sampalis, J	P81
Raffa, J	P277	Rodríguez-Arrondo, F	P33*	Sanchez, T	P134
Raffi, F	ES1.1, ES1.2	Rodríguez-Baños, J	P64	Sanchez Vera, M	P227
Ragazzoni, E	P243	Rodríguez-Nóvoa, S	P20, P66, P128	Sandova, O	P285
Rahim, S	P307	Rodríguez-Santiago, B	P142	Sandström, E	O41CH
Rajagopalan, R	P307, P311, P312, P318*	Roger, M	O114	Sang, E	O121
Rajjic, N	O425, P154, P198	Rojas, H	P252	Sanne, I	O124, P198
Rakhmanova, A	O332	Roldan, J	P102	Santoro, M	P35
Ramlagan, S	P73	Romanenko, O	P22	Santos, J	P102, P112
Ramos, J	P221	Romanescu, A	P257	Santos, JR	P58*, P191*
Randell, P	P129, P151	Romero, M	P268	Santos, N	P209
Ranneberg, B	P12*, P76	Romero, R	P284	Santos, S	P290
Rauch, A	P155	Romeu, J	P142	Sanz, J	P54, P92, P221, P251
Ravasio, V	O213	Rosa, C	P42	Sanz-Moreno, J	O415
Re, M	P123	Rosella, E	P74	Sarmiento, A	P296
Redfield, R	P121	Rosignoli, D	P118	Sarmiento-Castro, R	P51
Reekie, J	O331*	Rosing, H	P242	Sawyer, W	P5
Reeves, I	P203	Rosique-Robles, J	P162	Schapiro, J	O11CH, P191
Reeves, J	P197*	Rossi, M	P99	Schechter, M	PCH
Reichelt, D	P163	Rossi, P	P213	Scheen, R	P289
Reid, A	O125	Rossi, R	P94	Schepens, T	P228
Reiss, P	O212, O313, O314, O332, SS3CH, CS1CH, P27	Rosso, R	P215*	Scherer, J	P190, P192
Resino, S	P268	Rossotti, R	P194	Scheuerle, A	O221
Reynes, J	P29*	Rousseau, E	P208	Schewe, K	P13
Ribera, E	P36, P37*, P40, P44*, P53, P54*, P65, P134	Routy, J	O114	Schiaroli, E	P118
		Rovira, N	P143	Schmidt, E	P90
Ricci, E	P74	Rozsypal, H	P295	Schmidt, W	P7, P75
Richter, C	P55	Ruane, P	O413, P68*	Schmutz, G	P135, P160
Riddell, L	P15	Rubio, A	P66	Schneider, S	P22
Riddler, S	P312	Rubio, R	P54, P83*	Schnepf, N	P279*
Riekstina, V	O412	Rugina, C	P226	Schrager, H	O214
Riera, M	P40	Rugina, S	P226	Schwarze-Zander, C	P266, P304
Rietz, A	P91	Ruiz, L	P142	Sciandra, M	P233
Rimsky, L	P187, P189	Ruiz de Gopegui, E	P40	Sconiamilio, C	P34
Riordan, A	O122	Rusconi, S	P39, P194	Scorpan, C	P261
Ríos, M	P138, P141	Russo, R	P17	Scott, C	P49*
Ristola, M	P155	Ruta, S	P182, P275	Scott, JD	P303*
Ritchie, G	P271	Ruxrungtham, K	P157, P244	Scourfield, A	P14
Rivas, M	P40	Ryan, B	P37	Seaton, A	P103, P219, P225, P253, P291
Rivas, P	P128	Ryan, P	P137	Sedláček, D	P212*
Rivero, A	P141, P314	Ryan, R	O413, P36, P68	Seekins, D	P61, P185
Rizzardini, G	P3, P31	Sabin, C	O314, O422, SS6.1	Sellier, P	P279
Rizzi, L	P234	Sabo, J	P240	Seminari, E	P30*
Rjepaj, K	P87	Sa-Filho, D	P196, P209	Serra, P	P133
R-Junquera, M	P290	Saghayam, S	P111*	Sette, P	P166, P167, P169
Robertson, C	P249*	Saguenwong, N	P237	Sgrella, A	P10
Roca, B	P134				

*Indicates presenting author.



AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Shahar, E	P188	Staszewski, S	O41CH, P32, P76, P122	Terzi, R	P206
Shahmanesh, M	P113	Stellbrink, H	ES2.3, P7, P75	Tetradov, S	P224
Shallcross, V	P238	Stentarelli, C	P34, P94, P115, P125, P139, P140, P300	Thal, G	P136
Shantz, K	P229	Stephan, C	P13, P25*, P32*, P122*	Theofilopoulou, A	P85
Sharra, E	P87	Sterrantino, G	P3	Thi Dieu TA, N	P269
Sheehan, G	P109	Stevens, M	P239	Thibert, R	P298
Shehu, E	P87	Stoehr, A	P13	Thielen, A	P201
Sherlock, C	P271	Storfer, S	O23CH	Thiry, A	P8, P136, P185
Shewade, A	P318	Storms, M	P277	Thoden, J	P145*, P210
Shingadia, D	O122	Stradling, C	P249	Thompson, M	P27
Shivaji, G	P111	Streinu-Cercel, A	P255	Thornhill, J	P276
Shojaee-Moradie, F	P113	Stuermer, M	P32, P201	Thu Thuy, H	P77
Showler, G	P277	Suarez, I	P290	Thusgaard, M	P90*
Siccardi, M	P233*	Suarez-Lozano, I	P134	Tikhonova, E	P285
Sichtig, N	P201	Suleiman, J	P4	Tilekar, S	P303
Sighinolfi, L	P56	Sultana, C	P182	Tilson, H	O221
Silberman, B	P46	Sundaram, M	P111	Tincati, C	P1*, P88, P97*
Simon, A	P299	Sungkanuparph, S	P72	Tinelli, C	P30
Simoneau, G	P279	Suter, F	O213	Tissot, F	P231*
Simpson, K	P307*, P311*, P312*	Suwanmala, P	P259	Tobara, J	P209
Skiest, D	O214	Svard, J	P236*	Todd, J	P11
Skrahin, A	O412	Svedhem, V	P256*	Toibaro, J	O412
Smets, E	P313*, P316*	Svicher, V	P35	Tomaka, F	O424, P22
Smith, B	P230	Swai, E	P175	Tomasini, A	P177*
Smith, C	O333*, P6, P249, P250	Sypsa, V	P186	Tomaszewski, K	P154
Soddu, V	P19	Szczepańska-Putz, M	P216, P217	Tomé, M	O222
Sodemann, M	P174	Tagliabue, L	P153	Tomlinson, J	P113
Soentjens, P	P270	Talbird, S	P306, P309	Tookey, P	O122
Sogni, P	P287	Talwani, R	P121	Toraldo, G	P118
Solera, C	P128	Tamburrini, E	P168	Torres, R	P173
Solomon, S	P111	Tambussi, G	P45, P202	Torres Perea, R	P93, P100
Sonecha, S	P204*, P230	Tambuyzer, L	P181, P189	Torrise, C	P215
Sönnerborg, A	O11CH	Tampellini, L	P123	Tossonian, H	P277
Soria, A	P45, P202	Tappe, A	P13, P25, P43	Toy, J	P271
Soriano, V	O232*, P20, P66, P128, P137, P138, P265, P268, P284, P286	Tardei, G	P224, P275	Tozzi, V	P179, P292
Sorlí, M	P130*, P302	Tasaneeyapan, T	P259	Treacy, V	P132
Sotgiu, G	P56, P138	Taylor, C	O222	Trein, A	P7, P75
Sozio, F	P19, P152	Taylor, J	P129, P151	Tressler, R	P154, P198
Spagnuolo, V	P202	Taylor, K	P16	Trevino Perez, S	P104, P108
Spathis, A	P294	Taylor, N	P200*	Trinh, L	P197
Spiers, J	P91*, P236	Taylor, S	P249	Tripathi, A	P158*
Spinosa-Guzman, S	P21, P22, P24, P157	Tchidjou, H	P213	Trocha, H	O332
Spire, B	CoS.4	Teeratakulpisarn, N	P259*	Trotta, M	P166*, P167, P169*, P179
Spiridon, G	P287	Teicher, E	P299	Trout, H	P222
Sprenger, H	P55*	Teira, R	P134*	Trujillo-Santos, J	P164, P254
Squillace, N	P34, P94, P115*, P125, P139, P140, P156, P177, P300	Temereanca, A	P182	Truong Giang, L	P77
Srasuebkul, P	P72*	ten Berg, M	P60	Trylesinski, A	P279
Ssali, F	O125	ten Kate, R	P55	Tsang, A	P81
Stamatakis, G	P105	ten Napel, C	P55	Tsiodras, S	P294
Stanczak, G	P184*	Teofilo, E	P51, P76	Tsogas, N	P105
Stanczak, J	P184	Teppler, H	P207	Tsoupras, A	P105*
Stankova, M	P295	ter Heine, R	P242*	Tudor-Williams, G	O122
		Teresa, B	P97	Tuma, P	P137, P265*, P268, P284*
		Terron, A	P134	Tumukunde, D	O125
				Tural, C	P264
				Turner, D	P188*
				Turri, O	P235

* Indicates presenting author.

AUTHOR INDEX (continued)

Name	Activity	Name	Activity	Name	Activity
Tuyet Nhung, V	P77*	Vera-Méndez, F	P164*, P254*	Weber, R	O314, O32CH, P27
Umpleby, A	P113	Vergara, A	P134	Weller, IVD	O22CH, O42CH
Ungureanu, E	P224	Verlinden, Y	P187	Wellmann, E	P13, P25
Ungurianu, R	P255	Vescini, F	P123	Wendig, A	P122
Uniyal, A	P303	Vibhagool, A	P2	Weston, R	P204
Urbankova, O	P295	Vichi, F	P35, P74	Whitcomb, J	P197
Urbina, O	P302	Vicians, P	P134, P141	White, B	P291*
Usadel, S	P71	Victor, V	P120	Whiteside, A	KL3*
Ushiro-Lumb, I	P203	Vidal, F	P134	Wiercinska-Drapalo, A	O212, P184
Uy, J	P8*, P185*	Vidal, I	P146	Wiesmann, F	P43
Vachta, J	P43	Viergever, R	P60*	Wilkins, E	ES1CH, ES1.4
Vagu, C	P182	Viganò, O	P194, P274	Williams, I	O324*, CS2.2, CS2CH
Vaillancourt, J	P81	Vige, R	P90	Williams, P	P2
Valantin, M	P26, P269	Vignolo, M	P215	Winston, A	P260, P301
Valencia, E	P128	Vilaplana-García, R	P164, P254	Winter, A	P103, P219, P225, P253
Vallecillo, G	P130	Villalonga, C	P92	Wintergerst, U	O222
Van Baelen, B	O424	Villani, P	P234	Wirden, M	P29, P38
Van Cauwenberge, A	P205	Villar, J	P130, P302	Witek, J	O413, P68
Van De Castele, T	P21, P24	Villar del Saz, S	P40	Wolf, E	P7*, P13, P25, P195*, P201
van Delft, Y	P36	Vinci, C	P202	Wongsuthipol, C	P259
Van Den Boer, M	P270	Vingerhoets, J	P23, P181, P189*	Wood, C	O422
Van Der Borght, K	P187	Vinh Thuy, L	P77	Wood, R	O113, O123, O134*, P159, P198
van Der Lugt, J	P244	Visco, F	P45, P202	Woodward, W	P9
Van Der Ryst, E	P154	Visco-Comandini, U	P169	Workman, C	P22
van der Werf, T	P55	Viscoli, C	P215	Worm, S	O314
van Gorp, E	P242	Vispo, E	P128, P137, P138, P265, P268, P284, P286*	Wouters, K	P223
van Heeswijk, R	P239	Vitiello, P	P39*	Wrin, T	P197
Van Houtte, M	P187, P205	Vitiello, PV	P194	Wruck, J	P240
Van Laethem, Y	CS1.4	Vlieghe, E	P270, P283	Xerinda, S	P296
van Lunzen, J	O331, O423, P12, P41, P62	Vogel, M	P195, P266	Xilomenos, G	P124
van Solinge, W	P60	Vogt, E	P266, P304	Xynos, K	P124
Van Solingen-Ristea, R	P27	Volkov, Y	P91	Yang, R	P8, P136, P180
van Vugt, M	CS1.2	Volny-Anne, A	PCH, CoSCH	Yazdanpanah, Y	P26, P195
Van Walle, I	P195	von Hentig, N	P32, P122	Yerrakalva, D	P301
Vanaken, H	P36, P37	Voorspoels, E	P27	Youle, M	O333, P6, P250
Vandeloise, E	O415	Vriesendorp, R	P55	Young, B	P61*
Vandevoorde, A	P22	Wainberg, M	O114*	Zaccarelli, M	P166, P169, P179*
Vangeneugden, T	O424, P22, P157	Walensky, R	O113	Zaunders, J	P297
Vannappagari, V	O221	Walker, AS	O122*, O125	Zetehaku, A	P209*
Vanveggel, S	P2	Walker, U	P145, P147, P148, P210	Zhou, Y	P4
Varma, J	P259	Walli, R	P86	Zicolella, R	P152
Vecchiet, J	P19	Walter, H	P201	Zimovetz, E	P306
Vekemans, M	P270, P283	Wan, H	P207	Zirilli, L	P140
Velasco, M	P92	Wangpatharawanit, P	P232*	Zona, S	P34, P94, P115, P125, P139, P140, P177, P300
Velat, M	P130, P302	Wanke, C	P111	Zoufaly, A	O423*
Velhal, S	P211	Ward, D	P57*		
Vella, S	O21CH	Wasmuth, J	P266, P304		
Venhoff, A	P210	Watera, C	P11		
Venhoff, N	P145, P147*, P148*, P210*	Waters, L	O422*, SS4.1, P129*, P151*		
Vera, J	P51, P76	Watts, D	O221		

*Indicates presenting author.

